Home / news / Pharma companies meet to discuss market control, supply sustainability

Pharma companies meet to discuss market control, supply sustainability

Businessmen Team news 05 June 2025 01:43 PM
Share Article:
Pharma companies meet to discuss market control, supply sustainability

Dr. Ali El-Ghamrawy, Chairman of the Egyptian Drug Authority, held a meeting with representatives of pharmaceutical distribution companies as part of the Authority's commitment to strengthening cooperation with relevant partners.

The meeting discussed developing effective strategies to meet the needs of the local market. Visions were also exchanged on ways to enhance cooperation between the Authority and distribution companies to develop pharmaceutical policies, achieving a balance between sustainable development requirements and ensuring access to high-quality and efficient medicines. During the meeting, the priority of adopting flexible and comprehensive market mechanisms based on updated international standards was discussed. This will contribute to supporting transparency and stability in the pharmaceutical market.

Both parties emphasized the importance of continuing coordination and communication channels to keep pace with global changes and achieve integration between pharmaceutical and economic policies to ensure optimal benefits for the health and pharmaceutical sectors.

Attending from outside the Authority were Dr. Ghada Seddik, Head of the Branches Sector at the Egyptian Pharmaceutical Trading Company; Dr. Mahmoud Abdel Gawad, CEO of Ibnsina; Dr. Omar Abdel Gawad, Chairman of Ibnsina; Dr. William Mehani, Chairman of Ramco Pharm; Dr. Mohamed Galal, Vice Chairman of United Company; Dr. Mohab Jazzarin, Vice Chairman of the Board of Directors of Pharma Overseas, Dr. Ahmed Mohab Gazzarin, Member of the Board of Directors of Pharma Overseas, and Dr. Ahmed Saeed, Commercial Director of Pharma Overseas.

The meeting was held as part of the Egyptian Drug Authority's commitment to strengthening partnerships with relevant stakeholders and developing a pricing system that keeps pace with sustainable development requirements and serves the interests of all partners in the healthcare and pharmaceutical sectors.